A DNA vaccine encoding for TcSSP4 induces protection against acute and chronic infection in experimental Chagas disease

International Journal of Biological Sciences

Volumn 7, Issue 9, 2011, Pages 1230-1238

  Arce Fonseca, Minerva ^a,b   Ramos Ligonio, Angel ^a,c   López Monteón, Aracely ^a,c   Salgado Jiménez, Berenice ^a   Talamás Rohana, Patricia ^a   Rosales Encina, José Luis ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c UNIVERSIDAD VERACRUZANA   (Mexico)

Author keywords

DNA immunization; TcSSP4; Trypanosoma cruzi

Indexed keywords

ANIMALIA; EUKARYOTA; MURINAE; MUS; TRYPANOSOMA CRUZI;

EID: 81255128817     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.1230     Document Type: Article

References (43)

1. World Health Organization. Report of the scientific working group on chagas disease; Tech Rep. Buenos Aires, Argentina: UNDP/World Bank/WHO. 2006.
2. World Health Organization. First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. WHO: WHO/HTM/NTD Press. 2010.
3. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmis-sion in the Southern Cone countries. Mem Inst Oswaldo Cruz. 2003; 98: 577-591.
4. Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epi-demiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009; 104: 17-30.
5. Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Exp Rev Vacc. 2009, 8: 921-35.
6. Costa F, Franchin G, Pereira-Chioccola VL, et al. Immunization with a plasmid DNA containing the gene of trans-sialidase re-duces Trypanosoma cruzi infection in mice. Vaccine. 1998; 16: 768-74.
7. Sepulveda P, Hontebeyrie M, Liegeard P, et al. DNA-based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protec-tion against Trypanosoma cruzi infection. Infect Immun. 2000; 68: 4986-91.
8. Planelles L, Thomas MC, Alonso C, et al. DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elic-its a cytotoxic and humoral immune response against the anti-gen and leads to protection. Infect Immun. 2001; 69: 6558-63.
9. + T cell epitopes are im-portant for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun. 2001; 69: 5477-86.
10. Garg N, Tarleton R. Genetic immunization elicits anti-gen-specific protective immune responses and decreases dis-ease severity in Trypanosoma cruzi infection. Infect Immun. 2002; 70: 5547-55.
11. Boscardin SB, Kinoshita SS, Fujimura AE, et al. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elic-its protective immune response against experimental infection. Infect Immun. 2003; 71: 2744-57.
12. Brener Z, Gazzinelli RT. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol. 1997; 114: 103-10.
13. Tarleton RL. Immunity to Trypanosoma cruzi. In: Kaufmann SHE, ed. Host response to intracellular pathogens. Austin: RG Landes Co.; 1997: 227-47.
14. Tarleton RL, Zhang L. Chagas' disease etiology: autoimmunity or parasite persistence?. Parasitol Today. 1999; 15: 94-9.
15. Rottenberg ME, Bakhiet M, Olsson T, et al. Differential suscep-tibilities of mice genomically deleted of CD4 and CD8 to infec-tions with Trypanosoma cruzi or Trypanosoma brucei. Infect Im-mun. 1993; 61: 5129-33.
16. Tarleton RL, Koller BH, Latour A, et al. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature. 1992; 356: 338-40.
17. Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, et al. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. Vaccine. 2010; 28: 7414-19.
18. Miyahira Y, Takashima Y, Kobayashi S, et al. Immune re-sponses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun. 2005; 73: 7356-65.
19. Araujo AF, de Alencar BC, Vasconcelos JR, et al. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun. 2005; 73: 6017-25.
20. Martin DL, Weatherly DB, Laucella SA, et al. CD8+ T-cell re-sponses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006; 2: e77.
21. Padilla AM, Bustamante JM, Tarleton RL. CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol. 2009; 21: 385-90.
22. Ramos-Ligonio A, López-Monteon A, Talamás-Rohana P, et al. Recombinant Ssp-4 protein from Trypanosoma cruzi amastigotes regulates Nitric Oxide production by macrophages. Parasite Immunol. 2004; 26: 409-18.
23. Abrahamson I, Coffman R. Cytokine and nitric oxide regulation of the immunosuppression in Trypanosoma cruzi infection. J Immunol. 1995; 155: 3955-61.
24. Gutierrez Fredy RS, Mineo Tiago WP, Pavanelli Wander R, Guedes Paulo MM, Silva João S. The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz. 2009; 104(Suppl. I): 236-245.
25. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: Im-munology, application and optimization. Annnu Rev Immunol. 2000; 18: 927-74.
26. Khan IA, Schwartzman JD, Matsuura T, et al. A dichotomous role for nitric oxide during acute Toxoplasma gondii infection in mice. Proc Natl Acad Sci. 1997; 94: 13955-60.
27. Bocca AL, Hayashi EE, Pinheiro AG, et al. Treatment of Para-coccidioides brasiliensis-infected mice with a nitric oxide inhibitor prevents the failure of cell-mediated immune response. J Im-munol. 1998; 161: 3056-63.
28. Dai WJ, Gottstein B. Nitric oxide-mediated immunosuppres-sion following murine Echinococcus multilocularis infection. Immunology. 1999; 97: 107-16.
29. Stenberg J, McGuigan F. Nitric oxide mediates suppression of T cell response in murine Trypanosoma brucei infection. Eur J Immunol. 1992; 22: 2741-44.
30. Abrahamson I, Coffman R. Cytokine and nitric oxide regulation of the immunosuppression in Trypanosoma cruzi infection. J Immunol. 1995; 155: 3955-61.
31. Nascimento FR, Calich VL, Rodriguez D, et al. Dual role for nitric oxide in paracoccidioidomycosis: essential for resistance, but overproduction associated with susceptibility. J Immunol 2002; 168: 4593-600.
32. O'Farrell AM, Liu Y, Moore KW, et al. IL-10 inhibits macro-phage activation and proliferation by distinct signaling mecha-nism: evidence for Stat-3-dependent and-independent path-ways. EMBO J. 1998; 17: 1006-18.
33. Gurunathan S, Klinman DM, Seder RA. DNA Vaccines: Im-munology, application and optimization. Ann Rev Immunol. 2000; 18: 927-74.
34. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol. 2001; 31: 550-4.
35. Araujo F. Development of resistance to Trypanosoma cruzi in mice depends on a viable population of L3T41 (CD41) T lym-phocytes. Infect Immun. 1989; 57: 2246-8.
36. McCabe R, Meagher S, Mullins B. Gamma interferon sup-presses acute and chronic Trypanosoma cruzi infection in cyclo-sporin-treated mice. Infect Immun. 1991; 59: 1633-8.
37. Minoprio P, el Cheikh MC, Murphy E, et al. Xid-associated resistance to experimental Chagas disease is IFN-gamma de-pendent. J Immunol. 1993; 151: 4200-8.
38. Rottenberg ME, Riarte A, Sporrong L, et al. Outcome of infec-tion with different strains of Trypanosoma cruzi in mice lacking CD4 and/or CD8. Immunol Lett. 1995; 45: 53-60.
39. Hoft DF, Schnapp AR, Eickhoff CS, et al. Involvement of CD4+ Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi. Infect Immun. 2000; 68: 197-204.
40. Hoft DF, Eickhoff CS. Type 1 immunity provides optimal pro-tection against both mucosal and systemic Trypanosoma cruzi challenges. Infect Immun. 2002; 70: 6715-25.
41. Sepulveda P, Hontebeyrie M, Liegeard P, Mascilli A, Norris KA. DNA-Based immunization with Trypanosoma cruzi com-plement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infec Immun. 2000; 68: 4986-91.
42. Morell M, Thomas MCC, Caballero T, Alonso C, Lopez MC. The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosome cruzi infection. Vaccine. 2006; 24: 7046-55.
43. Fralish BH, Tarleton RL. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypa-nosoma cruzi infection. Vaccine. 2003; 21: 3070-80.